A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
11/7/2025
BreakingCataractGlaucomaRegulationRetinaSurgical
CMS’ Changes to Final 2026 Physician Fee Schedule Include Two Significant Cuts
The Centers for Medicare and Medicaid Services (CMS) made two significant cuts to parts of the formula used to calculate physicians’ Medicare procedure fees in 2026, despite heavy lobbying by the m...
11/7/2025
BreakingRegulationThyroid Eye Disease
Viridian Submits BLA to US FDA for Veligrotug in Thyroid Eye Disease
Viridian Therapeutics announced Nov. 3 that it had submitted a biologics license application (BLA) to the US FDA for veligrotug, the company’s intravenous treatment candidate for thyroid eye diseas...
11/7/2025
BreakingChinaDealsGene TherapyRetina
4DMT Licenses Retinal Gene Therapy Candidate to Otsuka for Asia-Pacific
4D Molecular Therapeutics announced Oct. 30 a strategic partnership with Otsuka Pharmaceutical Co. to develop and commercialize retinal gene therapy candidate 4D-150 in the greater Asia-Pacific (AP...
11/7/2025
BiosimilarsBreakingDry EyeGlaucomaIOLLaserPresbyopiaRetinaRevenueSurgicalThyroid Eye Disease
Q3-2025 Ophthalmic Revenue Roundup for Amgen, AbbVie, Hoya, Glaukos, Apellis, Astellas, and Four Others
Amgen, of Thousand Oaks, California, reported Nov. 4 that its Q3-2025 revenue from Tepezza was $560 million, a 15 percent increase over $488 million in Q3-2024. The total consisted of $518 million ...
11/7/2025
BiosimilarsBreakingDealsEuropeRetina
Samsung Bioepis to Commercialize Byooviz in Europe Starting in January 2026
South Korea’s Samsung Bioepis announced Oct. 29 that it would assume responsibility for the marketing of Byooviz (ranibizumab), a Lucentis biosimilar, in Europe upon the transfer of commercial righ...
11/7/2025
BreakingPharmaRegulationRetina
UK Accepts Conditional Marketing Application for Belite Bio’s Tinlarebant in Stargardt
Belite Bio announced Nov. 2 that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) had agreed to accept a conditional marketing authorization application for oral tinlarebant for ...
11/7/2025
BreakingClinical TrialGene TherapyRegulationRetina
FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON
France’s GenSight Biologics announced Oct. 30 that the FDA had granted permission for a single patient in the US to be treated with GS010, also known as Lumevoq, GenSight’s intravitreal gene therap...
11/7/2025
BreakingPharmaRegulationRetina
Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)
Outlook Therapeutics reported Nov. 3 that it had resubmitted its biologics license application (BLA) to the US FDA for ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet age-rela...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.